RRBP1 and breast carcinoma: Patel and Shah [38] demonstrated that Hes pretreatment (200 mg/kg) markedly reduced tumor incidence, oxidative stress, and inflammatory cytokine levels in a DMBA-induced breast cancer rat model, while simultaneously mitigating doxorubicin-related systemic toxicity.